Glycomet GP 1 (Metformin/Glimepiride)

Product Overview

Glycomet GP 1 is a prescription oral medication formulated for the management of type 2 diabetes mellitus. Each strip contains 15 sustained‑release tablets that combine two well‑established antihyperglycemic agents, metformin and glimepiride, in a fixed 500 mg/1 mg strength. The product is manufactured by USV Pvt Ltd and is supplied in packs of 30, 60, or 90 tablets, offering flexibility for long‑term therapy. Its sustained‑release design helps maintain steady plasma concentrations, reducing the frequency of dosing and supporting consistent glycemic control.

What is Glycomet GP 1

Glycomet GP 1 belongs to the class of oral antidiabetic drugs that target both hepatic glucose production and pancreatic beta‑cell insulin secretion. Metformin, the first component, decreases gluconeogenesis and improves insulin sensitivity, while glimepiride, a sulfonylurea, stimulates insulin release from the pancreas. The combination provides complementary mechanisms that address high fasting glucose and post‑prandial spikes, making it a valuable option when single‑agent therapy does not achieve target HbA1c levels.

Uses and Benefits

The primary use of Glycomet GP 1 is to lower blood glucose in adults with type 2 diabetes when diet and exercise alone are insufficient. Clinical studies demonstrate that the dual‑action formulation can achieve a reduction in HbA1c of up to 1.5 % compared with placebo, and it often produces greater improvements in fasting plasma glucose than metformin alone. Patients may also experience modest weight neutrality, which is advantageous for those who are overweight or obese. The sustained‑release tablet minimizes gastrointestinal upset, enhancing adherence to long‑term treatment regimens.

How It Works

The antidiabetic effect of Glycomet GP 1 arises from the synergistic action of its two active ingredients. Metformin activates AMP‑activated protein kinase, a cellular energy sensor that reduces hepatic glucose output and increases peripheral insulin sensitivity. Glimepiride binds to the sulfonylurea receptor on pancreatic beta cells, leading to closure of ATP‑sensitive potassium channels and subsequent calcium influx, which triggers insulin granule exocytosis. Together, these mechanisms lower fasting glucose, diminish post‑meal glucose excursions, and support overall glycemic stability.

Dosage Guidelines

Dosage of Glycomet GP 1 is individualized based on baseline glycemic control, renal function, and patient tolerance. Therapy typically begins with one tablet daily, taken with the morning meal, and may be titrated upward by 1 tablet at intervals of 1–2 weeks, not exceeding the maximum recommended dose of two tablets per day. The sustained‑release formulation should be swallowed whole; crushing or chewing is discouraged to preserve the release profile. Regular monitoring of kidney function and fasting glucose is advised to ensure the dose remains appropriate throughout treatment.

Side Effects

Like all antidiabetic agents, Glycomet GP 1 can be associated with adverse effects. The most frequently reported are gastrointestinal symptoms such as nausea, diarrhea, and abdominal discomfort, which are usually mild and transient. Rare but serious complications include hypoglycemia, particularly when used in combination with other insulin secretagogues or insulin, and lactic acidosis, a condition linked to metformin accumulation in patients with impaired renal function. Patients should be instructed to report persistent vomiting, muscle pain, or unexplained fatigue, as these may signal metabolic disturbances requiring prompt medical evaluation.

Warnings and Precautions

Patients should not use Glycomet GP 1 if they have severe renal impairment, defined as an estimated glomerular filtration rate below 30 mL/min/1.73 m², or if they have a history of metabolic acidosis, including diabetic ketoacidosis. Caution is advised in elderly individuals, those with hepatic disease, or those undergoing radiographic contrast procedures, as these conditions may increase the risk of lactic acidosis. It is essential to inform healthcare providers of all concomitant medications, especially those that affect renal function or glucose control, to avoid drug interactions. Pregnant or breastfeeding women should consult a physician before initiating therapy, as the safety profile in these populations has not been fully established.

Frequently Asked Questions

1. What are the active ingredients in Glycomet GP 1?

Glycomet GP 1 combines two oral hypoglycemic agents: metformin, which reduces hepatic glucose production and improves insulin sensitivity, and glimepiride, a sulfonylurea that stimulates insulin release from pancreatic beta cells. The fixed 500 mg/1 mg strength delivers a consistent dose of each component. For detailed pharmacology, refer to the NIH drug information page. Both agents are widely studied and approved by the FDA for the treatment of type 2 diabetes when used in conjunction with diet and exercise. The combination provides complementary mechanisms that can achieve greater A1C reductions than either agent alone.

2. How should I store Glycomet GP 1?

Store the tablets at room temperature, away from direct heat, moisture, and light. Keep the strip sealed until ready for use and discard any expired medication. Do not refrigerate or freeze unless instructed by a healthcare professional. Avoid storing the medication in the bathroom or near the kitchen sink where humidity may affect tablet integrity. Keep out of reach of children and pets. Proper storage helps maintain the drug’s potency throughout the treatment course. For official storage guidance, see the FDA drug label page.

3. Can I take Glycomet GP 1 with other diabetes medications?

Because glimepiride enhances insulin secretion, combining it with other insulin secretagogues, insulin therapy, or certain oral antidiabetic drugs may increase the risk of hypoglycemia. Healthcare providers typically review a patient’s full medication list before initiating treatment. For comprehensive interaction details, consult the Drugs.com product monograph which lists known drug interactions and precautions. Patients should also inform their physician about over‑the‑counter supplements, herbal products, and non‑prescription pain relievers, as some may affect renal function or glucose control. Close monitoring of blood glucose is recommended during the first few weeks of combined therapy.

4. What should I do if I miss a dose of Glycomet GP 1?

If you remember a missed dose within a few hours of the scheduled time, take it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule; do not double up to make up for the missed tablet. Consistency helps maintain steady blood glucose levels. For additional guidance, refer to the MedlinePlus medication guide which outlines dosing principles for antidiabetic agents.

5. Is Glycomet GP 1 safe for patients with kidney disease?

Metformin, one component of Glycomet GP 1, is cleared primarily by the kidneys; accumulation can lead to lactic acidosis in patients with severe renal impairment. The medication is generally not recommended when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m², and dose reductions are advised for moderate impairment. For detailed renal dosing recommendations, consult the FDA prescribing information which provides specific guidance on kidney function and dosing adjustments. Patients should have their kidney function checked regularly, especially after dosage changes, to ensure safe use.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)